Studies have demonstrated that MSLN triggers colon cancer progression; thus, MSLN immunohistochemistry is a powerful prognostic tool for colorectal carcinoma and anti-MSLN therapy could be effective in treating MSLN-positive CRC, even at advanced metastatic stage [25,26]. The gene discussed is MSLN; the disease is colorectal carcinoma.